SAN FRANCISCO - A federal judge on Thursday dismissed some of the class action claims against Iovance Biotherapeutics Inc. that accused the company of misleading investors by paying writers to promote its stock, ruling the plaintiff could not trace his stock to the disputed offering.
Categories / Securities
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Contempt for Musk clouds jury selection in Twitter takeover trial February 19, 2026
-
Ups and downs for Boeing investors February 18, 2026 -
